Background: Cardiovascular (CV) diseases are a leading cause of mortality and they are frequent in patients with the obstructive sleep apnea syndrome (OSAS). Objectives: In this study we investigated if OSAS influences CV function independently of other CV risk factors frequently present in these patients (e.g. obesity, high blood pressure). Methods: We compared plasma markers of endothelial dysfunction, asymmetric dimethylarginine (ADMA) and endothelin-1 (ET-1), and atherosclerosis progression (soluble fraction of the CD40 ligand, sCD40L) in OSAS patients with (n = 23) and without (n = 18) concurrent CV risk factors, as well as in healthy subjects (n = 23). Results: Plasma ADMA (p < 0.01) and sCD40L (p < 0.05) were abnormally increased in patients with OSAS versus healthy controls, but they were not influenced by the presence or absence of CV risk factors in OSAS. ET-1 levels were not different between the three groups of subjects studied. Conclusions: OSAS is associated with endothelial injury and atherosclerosis progression independently of other CV risk factors.

Keywords:
Sleep apnea, Biomarkers, Endothelial dysfunction, Atherosclerosis, Obesity
1.
Heart disease and stroke statistics: Update. 2005. American Heart Association.
2.
Murray CJ, Lopez AD: Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269–1276.
3.
Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, Popma JJ, Stevenson W: The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes. I. Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006;114:2850–2870.
4.
Zaninotto P, Mindell J, Hirani V: Prevalence of cardiovascular risk factors among ethnic groups: results from the Health Surveys for England. Atherosclerosis 2007;195:e48–e57.
5.
Smith SC Jr: Multiple risk factors for cardiovascular disease and diabetes mellitus. Am J Med 2007;120(suppl 1):S3–S11.
6.
Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D’Agostino R, Newman AB, Lebowitz MD, Pickering TG: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829–1836.
7.
Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J: Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea. Am J Respir Crit Care Med 2005;166:159–165.
8.
Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Nieto J, O´Connor GT, Boland LL, Schwartz JE, Samet JM: Sleep-disordered breathing and cardiovascular disease. Am J Respir Crit Care Med 2001;163:19–25.
9.
Peppard P, Young T, Palta M, Skatrud J: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378–1384.
10.
Marin JM, Carrizo SJ, Vicente E, Agusti AGN: Long-term cardiovascular outcomes in men with obstructive sleep apnea. Effects of treatment with CPAP. Lancet 2005;365:1046–1053.
11.
Dincer HE, O’Neill W: Deleterious effects of sleep-disordered breathing on the heart and vascular system. Respiration 2006;73:124–130.
12.
McNicholas WT, Bonsignore MR: Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007;29:156–178.
13.
Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho G: Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:613–618.
14.
de la Peña M, Barcelo A, Barbe F, Pierola J, Pons J, Rimbau E, Ayllon O, Agusti AG: Endothelial function and circulating endothelial progenitor cells in patients with sleep apnea syndrome. Respiration 2008;76:28–32.
15.
Kato M, Roberts-Thomson P, Phillips BG, Haynes WG, Winnicki M, Accurso V, Somers VK: Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000;102:2607–2610.
16.
Ip MSM, Tse HF, Lam B, Tsang KWT, Lam WK: Endothelial function in obstructive sleep apnea and response to treatment. Am J Respir Crit Care Med 2004;169:348–353.
17.
Imadojemu VA, Gleeson K, Quraishi SA, Kunselman AR, Sinoway LI, Leuenberger UA: Impaired vasodilator responses in obstructive sleep apnea improved with continuous positive airway pressure therapy. Am J Respir Crit Care Med 2002;165:950–953.
18.
Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002–2012.
19.
Cohen RA: The role of nitric oxide and other endothelium-derived vasoactive substances in vascular disease. Prog Cardiovasc Dis 1995;38:105–128.
20.
Boger RH, Vallance P, Cooke JP: Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl 2003;4:1–3.
21.
Vallance P, Leiper J: Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023–1030.
22.
Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842–1847.
23.
Boger RH, Maas R, Schulze F, Schwedhelm E: Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 2005;43:1124–1129.
24.
Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Strodter D, Simon BC, Mugge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Boger RH: Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination Investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006;152:493–498.
25.
Ip MSM, Lam B, Chan LY, Zheng L, Tsang KWT, Fung PCW, Lam WK: Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000;162:2166–2171.
26.
Ohike Y, Kozaki K, Iijima K, Eto M, Kojima T, Ohga E, Santa T, Imai K, Hashimoto M, Yoshizumi M, Ouchi Y: Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure – possible involvement of nitric oxide and asymmetric NG,NG-dimethylarginine. Circ J 2005;69:221–226.
27.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–415.
28.
Touyz RM, Schiffrin EL: Role of endothelin in human hypertension. Can J Physiol Pharmacol 2003;81:533–541.
29.
Grimpen F, Kanne P, Schulz E, Hagenah G, Hasenfuss G, Andreas S: Endothelin-1 plasma levels are not elevated in patients with obstructive sleep apnoea. Eur Respir J 2000;15:320–325.
30.
Jordan W, Reinbacher A, Cohrs S, Grunewald RW, Mayer G, Ruther E, Rodenbeck A: Obstructive sleep apnea: plasma endothelin-1 precursor but not endothelin-1 levels are elevated and decline with nasal continuous positive airway pressure. Peptides 2005;26:1654–1660.
31.
Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S: New markers of inflammation and endothelial cell activation. Part I. Circulation 2003;108:1917–1923.
32.
Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR: Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896–899.
33.
Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104–1111.
34.
Kobayashi K, Nishimura Y, Shimada T, Yoshimura S, Funada Y, Satouchi M, Yokoyama M: Effect of continuous positive airway pressure on soluble CD40 ligand in patients with obstructive sleep apnea syndrome. Chest 2006;129:632–637.
35.
Cooke JP, Dzau VJ: Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997;96:379–382.
36.
Cooke JP, Dzau VJ: Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997;48:489–509.
37.
Busse R, Fleming I: Regulation and functional consequences of endothelial nitric oxide formation. Ann Med 1995;27:331–340.
38.
Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141–1146.
39.
Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ: Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995;346:467–471.
40.
Celermajer DS: Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 1997;30:325–333.
41.
Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, Bosello O, Lechi A: Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. Int J Obes Relat Metab Disord 1999;23:936–942.
42.
Phillips BG, Narkiewicz K, Pesek CA, Haynes WG, Dyken ME, Somers VK: Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999;17:61–66.
43.
Saarelainen S, Hasan J: Circulating endothelin-1 and obstructive sleep apnoea. Eur Respir J 2000;16:794–795.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.